Open AccessAssociation of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
Author(s) -
Bryan P. Schneider,
Μolin Wang,
Milan Radovich,
George W. Sledge,
Sunil Badve,
Ann D. Thor,
David A. Flockhart,
Bradley A. Hancock,
Nancy E. Davidson,
Julie R. Gralow,
Maura N. Dickler,
Edith A. Perez,
Melody Cobleigh,
Tamara Shenkier,
Susan M. Edgerton,
Kathy D. Miller
Publication year - 2008
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2008.16.1612
Subject(s) - bevacizumab , medicine , vascular endothelial growth factor , genotype , oncology , breast cancer , hazard ratio , paclitaxel , genotyping , chemotherapy , cancer , gastroenterology , vegf receptors , biology , confidence interval , gene , biochemistry
No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom